TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20170591

Group type: EXPERIMENTAL
Intervention: Natural grape juice (18 ml/kg/day) for 1 month
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Natural pomegranate juice (240 ml/day) for 1 month
Number of subjects: 30
Study: 19102149

Group type: EXPERIMENTAL
Intervention: Medial patellofemoral ligament overlap and lateral patellar retinaculum release
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lateral patellar retinaculum release (control)
Number of subjects: 100
Study: 16113403

Group type: EXPERIMENTAL
Intervention: Counselling by health and nutrition workers at multiple contacts on exclusive breastfeeding for 6 months and appropriate complementary feeding practices thereafter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 11961400

Group type: COMPARATOR
Intervention: Calcitriol 0 microg (placebo)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Calcitriol 1 microg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Calcitriol 1.5 microg
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Calcitriol 2 microg
Number of subjects: 162
Study: 10406247

Group type: EXPERIMENTAL
Intervention: Topical pharyngeal anesthesia with 2% tetracaine/14% benzocaine spray
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conscious sedation alone (no pharyngeal anesthesia)
Number of subjects: 95
Study: 7486274

Group type: EXPERIMENTAL
Intervention: Isoflurane-N2O-O2 (IF)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol-N2O-O2 (PF)
Number of subjects: 40
Study: 2209278

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (2 gm) with metronidazole (1.5 gm)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Gentamicin (3 mg/kg/day for five days) with metronidazole (1.5 gm)
Number of subjects: 173
Study: 6993501

Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-relaxation (SR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transcendental Meditation (TM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 60
Study: 31259738

Group type: EXPERIMENTAL
Intervention: Tenofovir (1% gel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapivirine (25 mg in vaginal ring)
Number of subjects: 0
Study: 28937531

Group type: EXPERIMENTAL
Intervention: Intranasal DEX (2 μg/kg)
Number of subjects: 39
Study: 27307536

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study: 24908205

Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant
Number of subjects: 255

Group type: COMPARATOR
Intervention: Systemic therapy
Number of subjects: 255
Study: 23206205

Group type: EXPERIMENTAL
Intervention: HIV stereotypes
Number of subjects: 93

Group type: COMPARATOR
Intervention: Prejudice
Number of subjects: 93

Group type: COMPARATOR
Intervention: Discrimination
Number of subjects: 93

Group type: COMPARATOR
Intervention: Objective HIV risk
Number of subjects: 93
Study: 20480055

Group type: EXPERIMENTAL
Intervention: Terminalia chebula extract rinse
Number of subjects: 30

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 30
Study: 18278400

Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Infrared photocoagulation
Number of subjects: 48
Study: 15647412

Group type: EXPERIMENTAL
Intervention: Epoetin alfa, 40,000 IU/wk
Number of subjects: 48
Study: 12901592

Group type: EXPERIMENTAL
Intervention: Twinrix vaccine (0‐, 1‐, 6‐month vaccination schedule)
Number of subjects: 264
Study: 11051122

Group type: EXPERIMENTAL
Intervention: LEV 1500 mg twice daily (monotherapy)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: LEV 1500 mg twice daily (add-on phase)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: LEV 3000 mg/d (add-on phase)
Number of subjects: 286
Study: 8619442

Group type: EXPERIMENTAL
Intervention: Desferrioxamine B
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study: 1416842

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 287

Group type: COMPARATOR
Intervention: Cefadroxil
Number of subjects: 287
Study: 4020974

Group type: EXPERIMENTAL
Intervention: Mandatory surgery (group 1)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nonoperative management (group 2)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Mandatory surgery (group 3)
Number of subjects: 54
Study: 31770221

Group type: EXPERIMENTAL
Intervention: Hysterectomy and/or salpingectomy
Number of subjects: 238436

Group type: EXPERIMENTAL
Intervention: Hysterectomy and salpingectomy
Number of subjects: 238436

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 238436

Group type: EXPERIMENTAL
Intervention: Salpingectomy
Number of subjects: 238436

Group type: EXPERIMENTAL
Intervention: Bilateral salpingectomies
Number of subjects: 238436

Group type: COMPARATOR
Intervention: Comparison cohort (no surgeries)
Number of subjects: 238436
Study: 30089663

Group type: EXPERIMENTAL
Intervention: Predictive low-glucose suspend (PLGS) using Tandem Diabetes Care t:slim X2 pump with Basal‐IQ and Dexcom G5 sensor
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 103
Study: 26797931

Group type: COMPARATOR
Intervention: Pregnenolone pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 0
Study: 23913917

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 2076

Group type: EXPERIMENTAL
Intervention: Self-administered, computer-assisted self-management
Number of subjects: 2076

Group type: EXPERIMENTAL
Intervention: Self-administered program with enhanced social support
Number of subjects: 2076
Study: 22443839

Group type: EXPERIMENTAL
Intervention: Short family intervention with five weekly home‐based intervention sessions
Number of subjects: 151
Study: 20646413

Group type: EXPERIMENTAL
Intervention: uNGAL
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: uIL-18
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SCr
Number of subjects: 92
Study: 17968918

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 15764620

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: LDL-C
Number of subjects: 0
Study: 12032011

Group type: EXPERIMENTAL
Intervention: Clonidine 5 microg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clonidine (1 to 5 microg/kg)
Number of subjects: 80
Study: 11783181

Group type: EXPERIMENTAL
Intervention: Jinmaitong composita (JMTC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Jinkui Shenqi (JKSQ)
Number of subjects: 66
Study: 8907403

Group type: EXPERIMENTAL
Intervention: Peer-led drug prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adult-led drug prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 0
Study: 2350832

Group type: EXPERIMENTAL
Intervention: Tiao‐Zhi‐Tang (TZT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Inositol and Mai Tong
Number of subjects: 68
Study: 573558

Group type: EXPERIMENTAL
Intervention: Bupivacaine mixed with chloroprocaine (0.5 mg bupivacaine and 3 mg chloroprocaine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bupivacaine alone (0.5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chloroprocaine alone (3 mg)
Number of subjects: 20
Study: 31499231

Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) intervention
Number of subjects: 243

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 243
Study: 29233143

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 192

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 192
Study: 25486290

Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 24666268

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine and Methylphenidate
Number of subjects: 36
Study: 22511483

Group type: EXPERIMENTAL
Intervention: Silicone metacarpophalangeal joint arthroplasty (SMPA)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Nonsurgical control
Number of subjects: 162
Study: 19346430

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibition (ACEI)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study: 17617751

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 15118828

Group type: EXPERIMENTAL
Intervention: Anterior spondylodesis
Number of subjects: 22

Group type: COMPARATOR
Intervention: Anteroposterior spondylodesis
Number of subjects: 22
Study: 11939682

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin-tazobactam
Number of subjects: 98

Group type: COMPARATOR
Intervention: Intermittent infusion of piperacillin-tazobactam
Number of subjects: 98
Study: 9808683

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aspirin 300 mg three times daily
Number of subjects: 20
Study: 7663594

Group type: EXPERIMENTAL
Intervention: Graphic recording during mechanical ventilation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Graphic recording during spontaneous breathing
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (not specified) during mechanical ventilation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (not specified) during spontaneous breathing
Number of subjects: 44
Study: 2803986

Group type: EXPERIMENTAL
Intervention: Volume expansion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dihydralazine after volume expansion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dihydralazine alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dihydralazine before volume expansion
Number of subjects: 10
Study: 7447770

Group type: EXPERIMENTAL
Intervention: Once-a-day 0.25% timolol ophthalmic solution
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Twice-a-day 0.25% timolol ophthalmic solution
Number of subjects: 41
Study: 31530612

Group type: EXPERIMENTAL
Intervention: Team monitoring (clinical team monitoring with nursing outreach)
Number of subjects: 2750

Group type: EXPERIMENTAL
Intervention: Enhanced feedback (real-time feedback to patients about expected symptom severity)
Number of subjects: 2750

Group type: EXPERIMENTAL
Intervention: Enhanced feedback
Number of subjects: 2750
Study: 27956003

Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Anacetrapib 25 mg
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study: 25284089

Group type: EXPERIMENTAL
Intervention: elosulfase alfa 2.0mg/kg/week
Number of subjects: 176

Group type: COMPARATOR
Intervention: elosulfase alfa 2.0mg/kg/every other week
Number of subjects: 176

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 176
Study: 23663521

Group type: EXPERIMENTAL
Intervention: Person-centred proactive telephone support (daily for up to 14 days after hospital discharge)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Person-centred reactive support (mothers can phone the support team up to day 14 after hospital discharge)
Number of subjects: 1116
Study: 21864719

Group type: EXPERIMENTAL
Intervention: Chronic disease self-management support (CDSMS) using the Flinders Program for 6 months
Number of subjects: 252

Group type: COMPARATOR
Intervention: Attention control intervention (health information only) for 6 months
Number of subjects: 252
Study: 19762175

Group type: EXPERIMENTAL
Intervention: Recommendation to offer a pacifier
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no pacifier recommendation)
Number of subjects: 0
Study: 17881285

Group type: EXPERIMENTAL
Intervention: Mobile and internet intervention (SMS and website diary)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study: 15140339

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 15 mg
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 30 mg
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 45 mg
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 15 mg plus Sulfonylurea (SU)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 30 mg plus Sulfonylurea (SU)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) 30 mg plus Metformin (MET)
Number of subjects: 1000
Study: 11598535

Group type: EXPERIMENTAL
Intervention: LV5FU2 low dose
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: LV5FU2 high dose
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 5FU weekly
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tomudex(R)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Weekly 5FU
Number of subjects: 33
Study: 9291217

Group type: EXPERIMENTAL
Intervention: Clinician advice against tobacco use
Number of subjects: 13923

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 13923

Group type: EXPERIMENTAL
Intervention: Minority status
Number of subjects: 13923

Group type: EXPERIMENTAL
Intervention: Engagement in other risk practices
Number of subjects: 13923
Study: 8296582

Group type: EXPERIMENTAL
Intervention: Moclobemide (400 mg daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Open moclobemide
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 34

Group type: COMPARATOR
Intervention: Moclobemide and Placebo
Number of subjects: 34
Study: 3719424

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25% solution, 25 mg first dose, 10 ml, reinjections every hour for 10 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: 2-Chloroprocaine (2% solution, 200 mg first dose, 10 ml, reinjections every 30 min for 80 mg)
Number of subjects: 103
Study: 11454179

Group type: EXPERIMENTAL
Intervention: IFN‐alpha/amantadine sulphate
Number of subjects: 55

Group type: COMPARATOR
Intervention: IFN‐alpha/placebo
Number of subjects: 55

Group type: COMPARATOR
Intervention: IFN‐alpha
Number of subjects: 55
Study: 31218738

Group type: EXPERIMENTAL
Intervention: Educational intervention to improve OAC prescription
Number of subjects: 246

Group type: COMPARATOR
Intervention: Current clinical practice (Control)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Inappropriately prescribed OACs
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Inappropriately not prescribed OACs
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Prescription of OACs at admission
Number of subjects: 246
Study: 29474843

Group type: EXPERIMENTAL
Intervention: Stainless steel staples
Number of subjects: 242

Group type: COMPARATOR
Intervention: Subcuticular suture
Number of subjects: 242
Study: 27460100

Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (40 mg pantoprazole plus 1 g amoxicillin twice a day for 5 days, then 40 mg pantoprazole and 500 mg clarithromycin twice a day and 500 mg metronidazole three times a day for 5 days)
Number of subjects: 390

Group type: COMPARATOR
Intervention: 14-day modified bismuth quadruple therapy (40 mg pantoprazole, 600 mg bismuth subcitrate, 1 g tetracycline, and 1 g amoxicillin, twice a day)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Modified bismuth quadruple therapy
Number of subjects: 390
Study: 24392946

Group type: EXPERIMENTAL
Intervention: Once weekly 56.5 μg teriparatide
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 22569710

Group type: EXPERIMENTAL
Intervention: OCP + GnRH agonist
Number of subjects: 300

Group type: COMPARATOR
Intervention: OCP + GnRH antagonist
Number of subjects: 300
Study: 20332770

Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg once daily for 28 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo once daily for 28 days
Number of subjects: 48
Study: 17383926

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BoNT) injections into the submandibular glands
Number of subjects: 0

Group type: COMPARATOR
Intervention: Botulinum neurotoxin (BoNT) injections into the parotid glands
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison between submandibular and parotid injections
Number of subjects: 0
Study: 15709833

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other forms of treatment (pharmacotherapy either alone or in combination with family therapy)
Number of subjects: 0
Study: 12116726

Group type: COMPARATOR
Intervention: 0.28% triclosan/5% pyrophosphate/0.145% sodium fluoride, 0.2% triclosan/0.5% zinc citrate/0.112% sodium fluoride, 0.145% sodium fluoride and 0.15% sodium monofluorophosphate (applied neat and undiluted via a performed tooth shield)
Number of subjects: 185

Group type: COMPARATOR
Intervention: 0.28% triclosan/5% pyrophosphate/0.243% sodium fluoride, 0.3% triclosan/2% Gantrez copolymer/0.24% sodium fluoride (1:3 aqueous slurry rinses)
Number of subjects: 185

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine, 0.045% triclosan in ethanol plus respective vehicle placebos (mouthrinses)
Number of subjects: 185
Study: 10422923

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Continuous femoral block
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intravenous patient-controlled morphine
Number of subjects: 56
Study: 7766565

Group type: EXPERIMENTAL
Intervention: 50 g raw potato starch (550 g RS/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 50 g pregelatinized potato starch (0 g RS/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30 g pregelatinized potato starch plus 20 g lactulose (670 g indigestible disaccharide/kg)
Number of subjects: 10
Study: 2288551

Group type: EXPERIMENTAL
Intervention: VT = 12 ml/kg (group 1)
Number of subjects: 103

Group type: COMPARATOR
Intervention: VT = 6 ml/kg (group 2)
Number of subjects: 103
Study: 6969109

Group type: EXPERIMENTAL
Intervention: Cephalothin prophylaxis administered intraoperatively
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cephalothin prophylaxis administered both intraoperatively and postoperatively
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3
Study: 31993637

Group type: EXPERIMENTAL
Intervention: Financial incentives of €350 for 12-month continuous smoking abstinence
Number of subjects: 604
Study: 31203212

Group type: EXPERIMENTAL
Intervention: Pegloticase (8 mg every 2 weeks)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 31417058

Group type: EXPERIMENTAL
Intervention: Once daily dose of ferrous sulphate (65 mg elemental iron)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Twice daily dose of ferrous sulphate (130 mg elemental iron)
Number of subjects: 182
Study: 28524699

Group type: EXPERIMENTAL
Intervention: Nifedipine CR (80 mg)/candesartan (8 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg)/candesartan (8 mg)
Number of subjects: 51
Study: 26563714

Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting (EVH)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Open vein harvesting (OVH)
Number of subjects: 228
Study: 23983995

Group type: EXPERIMENTAL
Intervention: High Frequency Positive Pressure Mechanical Ventilation (HFPPV)
Number of subjects: 0
Study: 20925019

Group type: COMPARATOR
Intervention: Chenodesoxycholic acid (CDCA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Prednisolone (30 mg for 6 days)
Number of subjects: 12
Study: 19951216

Group type: EXPERIMENTAL
Intervention: Purified red clover (Trifolium pratense) isoflavone (86 mg/day) tablets
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17294808

Group type: EXPERIMENTAL
Intervention: Trimetazidine tablets (two brands)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 20
Study: 15368898

Group type: EXPERIMENTAL
Intervention: Computer game with unknown direction of movement of the center of pressures
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Computer game with strictly defined postural coordination
Number of subjects: 53
Study: 11703344

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) - 2 mg 17‐beta‐oestradiol and 1 mg norethisterone acetate
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 9391827

Group type: EXPERIMENTAL
Intervention: Self-reports of disease from relatives (case group)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Self-reports of disease from relatives (control group)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Differential participation analysis
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Informant characteristics
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Willingness to provide self-reports
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Consideration of differential selection
Number of subjects: 725
Study: 7704285

Group type: EXPERIMENTAL
Intervention: Low sodium intake (44 mmol sodium per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High sodium intake (290 mmol sodium per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Salt repletion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Salt depletion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Salt sensitivity vs. salt resistance
Number of subjects: 30
Study: 3107487

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 30691767

Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shockwave therapy (rESWT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21